The Union Health Ministry has proposed amendments to the Drugs Rules, 1945, to allow the immediate suspension of manufacturing licences for medicines declared Not of Standard Quality (NSQ) on specified critical quality parameters. The proposed changes aim to strengthen regulatory action against manufacturers of substandard medicines and enable authorities to intervene promptly when serious quality concerns are identified. According to the government, the amendments are intended to prevent the continued manufacture and distribution of drugs that fail prescribed quality standards. The proposal places patient safety and public health at the centre of the regulatory framework. Under the proposed mechanism, manufacturing licence suspensions would continue until the manufacturer undertakes corrective action. The amendment also provides for mandatory corrective measures before the suspension can be revoked. The proposal seeks to establish a more immediate response to critical quality failures, rather than allowing potentially substandard medicines to remain in production while regulatory processes continue. The development comes amid ongoing efforts to strengthen pharmaceutical quality control and ensure that medicines manufactured and distributed in India meet prescribed standards. The proposed amendments are expected to provide regulators with a mechanism to respond more effectively to serious drug quality violations. However, the changes are still at the proposal stage. Their final provisions and implementation would depend on the formal regulatory process and the text of the notified amendments. The proposed move could strengthen oversight of pharmaceutical manufacturing by linking the continuation of suspended licences to corrective action by the manufacturer.

AdvertisementThe Puranic